ArticleJTO clinical and research reports2021

Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic NSCLC: Brief Report on a Randomized, Open-Label, Phase 1b/2 Study (LUC2001 JNJ-54767414).

Rathi N Pillai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.